Monopar Therapeutics (MNPR) Accounts Payables (2016 - 2025)

Monopar Therapeutics has disclosed Accounts Payables across 10 years of filings, most recently posting $2.7 million for Q4 2025.

• Accounts Payables for Q4 2025 came in at $2.7 million, up 21.33% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.7 million (up 21.33% YoY), and the FY2025 annual result was $2.7 million, up 21.33% from the prior year.
• Accounts Payables came in at $2.7 million for Q4 2025 at Monopar Therapeutics, up from $2.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $3.1 million in Q4 2022 to a low of $806272.0 in Q1 2021.
• The 5-year median for Accounts Payables is $1.7 million (2023), against an average of $1.8 million.
• Across the five-year window, Accounts Payables jumped 168.85% in 2023 and tumbled 56.45% in 2024, its largest moves.
• Monopar Therapeutics' Accounts Payables stood at $1.6 million in 2021, then surged by 97.96% to $3.1 million in 2022, then tumbled by 43.83% to $1.8 million in 2023, then increased by 28.28% to $2.3 million in 2024, then rose by 21.33% to $2.7 million in 2025.
• The last three Accounts Payables figures came in at $2.7 million (Q4 2025), $2.6 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.